Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model

Atherosclerosis

Volumn 125, Issue 2, 1996, Pages 171-182

  Golomb, Gershon ^a   Fishbein, Ilia ^a   Banai, Shmuel ^b   Mishaly, David ^a   Moscovitz, Dorit ^a   Gertz, S David ^a   Gazit, Aviv ^c   Poradosu, Enrique ^c   Levitzki, Alexander ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BIKUR CHOLIM HOSPITAL   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Controlled release; Drug implants; Implantable drug delivery system; Protein tyrosine kinase; Restenosis; Tyrphostin

Indexed keywords

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ETHYLENE VINYL ACETATE COPOLYMER; PROTEIN TYROSINE KINASE INHIBITOR; RG 50872; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENZYME INHIBITION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE PREPARATION;

EID: 0030572772     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05868-6     Document Type: Article

References (71)

1. [1] Pompa JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426.
2. [2] Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s: choosing appropriate experimental animal model for the prevention of restenosis. Circulation 1992;85:1630.
3. [3] Serruys PW, Foley DP, de Feyter PJ. Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angiography. Br Heart J 1992;68:417.
4. [4] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
5. [5] Kakuta T, Currier JW, Haudenchild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809.
6. [6] Gertz SD, Gimple LW, Banai S, Ragosta M, Powers ER, Roberts WC, Perez LS, Sarembock IJ. Geometric remodeling is not the principal pathogenic process in restenosis after balloon angioplasty. Circulation 1994;90:3001.
7. [7] Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post-PTCA restenosis: dependence on the lesion substrate. Thromb Haemost 1995;74:552.
8. [8] Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992;19:418.
9. [9] Schwartz RS, Holmes DRJ, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284.
10. [10] Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: part II. Drugs 1993;46:249.
11. [11] Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: part I. Drugs 1993;46:18.
12. [12] Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce direct migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266.
13. [13] Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155.
14. [14] Adams PC, Badimon JJ, Badimon L, Chesebro JH, Fuster V. Role of platelets in atherogenesis: relevance to coronary arterial restenosis after angioplasty. Cardiovasc Clin 1987;18:49.
15. [15] Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990;111:2149.
16. [16] Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129.
17. [17] Jawien A, Bowen-Pope DF, Linder V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;(89):507.
18. [18] Kraiss LW, Raines EW, Wilcox JN, Seifert RA, Barrett TB, Kirkman TR, Hart CE, Bowen-Pope DF, Ross R, Clowes AW. Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J Clin Invest 1993;92:338.
19. [19] Weinstein R, Wenc K. Growth factor responses of human arterial endothelial cells in vitro. Cell Dev Biol 1986;22:549.
20. [20] Lindner V, Reidy MA, Fingerle J, Regrowth of arterial endothelium, Denudation with minimal trauma leads to complete endothelial cell regrowth. Lab Invest 1989;61: 556.
21. [21] Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739.
22. [22] Badesch DB, Lee PD, Parks WC, Stenmark KR. Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun 1989;160:382.
23. [23] Booth BA, Bar RS, Boes M, Dake BL, Bayne M. Cascieri M. Intrinsic bioactivily of insulin-like growth factor-binding proteins from vascular endothelial cells. Endocrinology 1990;127:2630.
24. [24] Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery 1991;18:197.
25. [25] Bjorkerud S. Effects of transforming growth factor-β I on human arterial smooth muscle cells in vitro. Arterioscler Thromb 1991;11:892.
26. [26] Cai JP, Falanga V, Chin Y-H. Transforming growth factor-β regulates the adhesive interactions between mononuclear cells and microvascular endothelium. J Invest Dermatol 1991;97:169.
27. [27] Gay CG, Winkles JA. Interleukin-1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1991;88:296.
28. [28] Grosenbaugh DA, Amoss MS, Hood DM, Morgan SJ, Williams JD. Epidermal growth factor-mediated effects on equine vascular smooth muscle cells. Am J Physiol 1988;255:C477.
29. [29] Casseells W. Smooth muscle cell growth factors. Prog Growth Factor Res 1991;3:177.
30. [30] Newby AC, George SJ. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 1993;(27):1173.
31. [31] Casseells W, Lappi DA, Baird A. Molecular atherectomy for restenosis. Trends Cardiovasc Med 1993;3:235.
32. [32] Deuel T. Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol 1987;3:443.
33. [33] Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443.
34. [34] Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;(61):203.
35. [35] Levitzki A. Tyrphostins: tyrosine kinase blockers as novel anti-proliferative agents and dissectors of signal transduction. FASEB J 1992;6:3275.
36. [36] Bilder GE. Krawiec JA, McVety K, Gazit A, Gilon C. Lyall R, Zilberstem A, Levitzki A, Perrone MH, Schreiber AB. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol 1991;260:C721.
37. [37] Shimokado K, Yokota T, Umezawa K, Sasaguri T, Ogata J. Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Atherioscler Thromb 1994;14:973.
38. [38] Shimokado K, Yokota T, Kosaka C. Zen K, Sasaguri T, Masuda J, Ogata J. Protein tyrosine kinase inhibitors inhibit both proliferation and chemotaxis of vascular smooth muscle cells. Ann NY Acad Sci 1995;748:171.
39. [39] Bilder GE, Kasiewski CJ, Walczak EM. Perrone MH. PDGF-receptor protein tyrosine kinase activity in carotid artery is enhanced by injury and inhibited in vivo by tyrphostin RG 13291. Drug Dev Res 1993;29:158.
40. [40] Clowes AW. Reidy MA. Clowcs MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of cndothclium. Lab Invest 1983:49:327.
41. [41] Okada T, Bark DH, Mayberg MR. Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anti-coagulation. Neurosurgery 1989;25:892.
42. [42] Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA 1990;87:3773.
43. [43] Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67.
44. [44] Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243.
45. [45] Simons M, Edelman ER, Rosenberg RD. Antisense proliferating, cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 1994;93:2351.
46. [46] Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992;89:465.
47. [47] Golomb G, Langer R, Schoen FJ, Smith SM, Choi Y, Levy RJ. Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. J Controlled Rel 1986;4:181.
48. [48] Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989;32:2344.
49. [49] Golomb G, Wagner D. Characterization and anti-calcification effects of implantable polyurethane matrices containing amorphous dispersion of bisphosphonic acid. Clin Materials 1991;8:33.
50. 3H]tetraeycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm Res 1992;9:1018.
51. [51] Ramdas L, McMurray JS, Budde RJA. The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability. Cancer Res 1994;54:867.
52. [52] Ron E, Turek T, Mathiowitz E, Chasin M, Hageman M, Langer R. Controlled release of polypeptides from polyanhydrides. Proc Natl Acad Sci USA 1993;90:4176.
53. [53] Castantino HR, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized insulin. Phram Res 1994;11:21.
54. [54] Roseman TJ, Higuchi WI. Release of medroxyprogesterone acetate from a silicone polymer. J Pharm Sci 1970;59:353.
55. [55] Miller ES, Peppas NA, Winslow DN. Morphological changes of ethylene/vinyl acetate-based controlled delivery systems during release of water soluble solutes. J Memb Sci 1983;14:79.
56. [56] Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ. Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 1987;76(4):271.
57. [57] Wilensky RL, March KL, Hathaway D, Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J 1991;122:1136.
58. [58] Wilensky RL, March KL, Gradus-Pizlo I, Spaedy AJ, Hathaway DR. Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc Med 1993;3(5):163.
59. [59] Wilensky RL, March KL, Gradus-Pizlo I, Schauwecker D, Michaels M, Robinson j, Carlson K, Hathaway DR. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J 1995;12:852.
60. [60] Wolinsky H, Lin C. Use of the perforated balloon catheter to infuse marker substances into diseased coronary artery walls after experimental post-mortem angioplasty. J Am Coll Cardiol 1991;17(6):174B.
61. [61] Wolinsy H. Local delivery: let's keep our eyes on the wall. J Am Coll Cardiol 1994;24(3):825.
62. [62] Gradus-Pizlo I, Wilensky RL, March KL, Finberg N, Michaels M, Sandusky GE, Hathaway DR. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J Am Coll Cardiol 1995;26:1549.
63. [63] Levy RJ, Golomb G, Trachy J. Labhasetwar V, Muller D, Topol E. Strategies for treating arterial restenosis using polymeric controlled release implants. In: Gebelein CG, ed. Biotechnology and Bioactive Polymers. Edgewater: Lionfire, Inc. 1994: 259.
64. [64] Burger AM, Kaur G, Alley MC, Supko JG, Malespeis L, Grever MR, Sausville EA. Tyrphostin AG-17, [(3,5-ditert-butyl-4-hydroxybenzylidene)-malononitrile]. inhibits cell growth by disrupting mitochondria. Cancer Res 1995;55:2794.
65. [65] Wolbring G, Hollenberg MD, Schnetkamp PPM. Inhibition of GTP-utilizing enzymes by tyrphostins. J Biol Chem 1994;269:22470.
66. [66] Munoz E, Zubiaga A, Huang C, Huber BT. Interleukin-l induces protein tyrosine phosphorylation in T cells. Eur J Immunol 1992;22:1391.
67. [67] Padeh S, Levitzki A, Gazit A, Mills GB, Roifman CM. Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. J Clin Invest 1991;87:1114.
68. [68] Melamed I, Downey GP, Roifman C. Tyrosine phosphorylation is essential for microfilament assembly in B lymphocytes. Biochem Biophys Res Commun 1991;176:1424.
69. [69] Ferns GAA, Reidy MA, Ross R. Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absense of functional T-lymphocytes. Am J Pathol 1991;138:1045.
70. [70] Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Ivan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligonucleotides. J Clin Invest 1994;93:820.
71. [71] Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense? Circulation 1993;88/3:1351.